Zacks Investment Research upgraded shares of Abcam (OTCMKTS:ABCZY) from a hold rating to a buy rating in a report published on Friday. The brokerage currently has $18.00 price target on the stock.

According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “

Abcam (OTCMKTS:ABCZY) traded up $0.29 during mid-day trading on Friday, hitting $16.47. The stock had a trading volume of 1,245 shares, compared to its average volume of 843. Abcam has a one year low of $9.76 and a one year high of $16.75.

TRADEMARK VIOLATION WARNING: “Abcam (ABCZY) Upgraded to Buy by Zacks Investment Research” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/abcam-abczy-upgraded-to-buy-by-zacks-investment-research/1815825.html.

Get a free copy of the Zacks research report on Abcam (ABCZY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.